EG 427 develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and its ability to establish lifelong latency in peripheral neurons to ensure highly specific and durable expression of transgenes to treat patients with severe, chronic and localized diseases, enabling physicians to cure neurogenic bladder disorders post a spinal cord injury.

Reverb Therapeutics uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokine, enabling cancer patients and the healthcare sector to redirect endogenous cytokines already in the body to cells of interest and treat cancer.

EnPlusOne Biosciences offers enzymatic-based RNA synthesis to address systemic issues inherent to existing chemical synthesis methods and the expansion of RNA therapeutics has uncovered key issues including scaled production and access to innovative therapeutic modifications, enabling the manufacturing process to deliver therapeutic RNA at a commercial scale sustainably.

Humane Genomics offers RNA-based viral therapies with selective infection, high lytic activity, and systemic delivery, enabling cancer patients to receive targeted, safe, and effective treatment with extended therapeutic duration.